☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Graft-Versus-Host Disease
Incyte Reports Results of Itacitinib in GRAVITAS-301 P-III Study for Patients with Treatment-Naive Acute Graft-Versus-Host Disease
January 3, 2020
The US FDA Lifts Clinical Hold for MaaT Pharma’s MaaT013 to Treat Acute Graft-versus-Host Disease
April 24, 2023
REGiMMUNE Entered into a License Agreement with San Fu Biotech to Develop and Commercialize RGI-2001 for the Prophylaxis of Acute...
April 3, 2023
AltruBio Reports the Completion of Patient Enrollment in P-I Clinical Study of Neihulizumab (ALTB-168) for Steroid-Refractory Acut...
May 13, 2022
Incyte’s Jakavi (ruxolitinib) Receives EC’s Approval as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host D...
May 5, 2022
Equillium Reports Initiation of P-III (EQUATOR) Study for Itolizumab as 1L Treatment of Acute Graft-Versus-Host Disease
March 7, 2022
Incyte Enters into an Exclusive WW License Agreement with Syndax to Develop and Commercialize Axatilimab for cGVHD and Other Fibro...
September 27, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.